Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.

Gynecologic oncology - 1 Aug 2021

Imboden Sara, Nastic Denis, Ghaderi Mehran, Rydberg Filippa, Siegenthaler Franziska, Mueller Michael D, Rau Tilman T, Epstein Elisabeth, Carlson Joseph W

Abstract excerpt

INTRODUCTION: In 2021, a joint ESGO/ESTRO/ESP committee updated their evidence-based guidelines for endometrial cancer, recommending a new risk grouping incorporating both clinicopathologic and molecular parameters. We applied the new risk grouping and compared the results to those of the prior 2016 clinicopathologic system. MATERIALS AND METHODS: We classified molecularly a cohort of 604 women diagnosed with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mismatch Repair
Share to DNA Polymerase II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Evidence-Based Medicine

Share to Feasibility Studies

Share to Medical Oncology

Share to Microsatellite Instability

Share to Poly-ADP-Ribose Binding Proteins

Share to Practice Guidelines as Topic

Source

Identifiers

PMID: 34127276
DOI: 10.1016/j.ygyno.2021.05.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.PMID 34127276Read ↗

Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancerSemantic proximity Read ↗

Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practiceSemantic proximity Read ↗

Application of novel algorithm on a retrospective series to implement the molecular classification for endometrial cancer.Semantic proximity Read ↗

Application of novel algorithm on a retrospective series to implement the molecular classification for endometrial cancer.Semantic proximity Read ↗

Analysis of Differences in the Classification of Endometrial Cancer Patients in PolandSemantic proximity Read ↗

FIGO 2023 staging system with/without molecular classification vs. FIGO 2009 in 172 endometrial cancer patients.Semantic proximity Read ↗

Association of Molecular Classification with FIGO Stage and Survival Outcomes in Endometrial Cancer.Semantic proximity Read ↗

Molecular classification-driven stage migration and prognostic risk stratification in endometrial cancers: FIGO 2023 vs FIGO 2009.Semantic proximity Read ↗

FIGO 2023 Staging and Molecular Classification of 172 patients with Endometrial CancerSemantic proximity Read ↗

New clinicopathological concept of endometrial carcinoma with integration of histological features and molecular profiles.Semantic proximity Read ↗

Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.Semantic proximity Read ↗

Molecular Characterization and Clinical Implications of Endometrial Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.